Therapie des metastasierten kolorektalen Karzinoms |
| |
Authors: | PD Dr. A. Reinacher-Schick |
| |
Affiliation: | 1. Knappschaftskrankenhaus, Medizinische Universit?tsklinik, In der Schornau 23–25, 44892, Bochum, Deutschland
|
| |
Abstract: | Treatment of advanced colorectal carcinoma (aCRC) has changed considerably over the past few years and is becoming increasingly individualized. In addition to highly effective chemotherapeutics, monoclonal antibodies became available for treating CRC a few years ago. The decision as to the type and duration of treatment now heavily depends on the extent of the disease and whether the patient is symptomatic. The existence of certain genetic changes also affects the choice of substance. The aim of palliative treatment remains to extend the patient’s life and to improve quality of life. In a patient group with primarily non-resectable liver metastases that may become resectable following a reduction in size, intensive neoadjuvant therapy can create the option of secondary surgical removal of the tumor manifestations and thus potentially cure the patients. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|